Weekly Subcutaneous <scp>VK2735</scp> , a <scp>GIP</scp> / <scp>GLP</scp> ‐1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13‐Week <scp>VENTURE</scp> Study